source
- Genmab’s cancer bispecific delivers early survival win in ‘exceedingly positive’ Phase 3 readoutAnalysts hailed the Phase 3 head and neck cancer results as a big victory for an asset central to Genmab’s growth plans.BioSpace · 13d ago↗ source
- Lilly’s ‘triple-G’ drug tops Novo’s Ozempic in diabetes trialThe highest dose of retatrutide beat Ozempic on measures of blood sugar and weight loss, but was also associated with higher side effect rates and treatment discontinuations.BioPharma Dive · 13d ago↗ source
- STAT+: Lilly’s triple-G drug beats Ozempic in head-to-head studyEli Lilly announced that its investigational drug retatrutide was more effective at lowering blood sugar and cutting weight than Novo Nordisk’s Ozempic in a large diabetes study.